Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABI vs IPOD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IPOD Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 9–0 Matrix Metrics)

IPOD Overall Winner 6-Pillar Tally: ABI 0 – 3 IPOD (3 Tie) Matrix Metrics: ABI 0 – 9 IPOD

As of Nov 16, 2026, IPOD (IPOD) is the stronger overall head-to-head candidate over ABI (ABI) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABI carries a Unified Composite Score of 49.0/100 (HOLD) at $24.48 (N/M Forward P/E, N/A operating margin), whereas IPOD carries 58.0/100 (HOLD) at $10.42 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ABI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.1); meanwhile IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABI vs IPOD
ABI US Equity
ABI
Institutional Equity
$24.48
-0.04% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.02β · 2% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 49.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.4%) with fading momentum, RSI 40
RSI-14: 40.1 · SMA20: $24.55 · SMA50: $24.55
IPOD US Equity Head-to-Head Winner
IPOD
Institutional Equity
$10.42
+0.39% 1D
Market Cap $210.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.00β · 2% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (ABI 0 – 3 IPOD)

Columns: Metric · ABI · IPOD
1. Valuation Multiples IPOD
Forward P/E N/M N/M
Trailing P/E N/M 39.9x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale IPOD
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $210.0M
3. Profitability & Quality IPOD
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A 0.0%
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Shell Companies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABI (0) vs IPOD (9)
Institutional Metric ABI IPOD Criterion Row Edge
Market Capitalization
Scale
N/A $210.0M Larger Scale IPOD
Trailing P/E Ratio
Valuation
N/M 39.9x Lower Multiple IPOD
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth IPOD
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin IPOD
Net Profit Margin
Profitability
N/A 0.0% Higher Margin IPOD
Return on Equity (ROE)
Capital Efficiency
N/A 0.0% Higher ROE IPOD
52-Week Range Position
Momentum
16% ($24–$25) 100% ($10–$10) Stronger Trend IPOD
Beta / 30D Volatility
Risk Regime
0.02β · 2% Vol 0.00β · 2% Vol Lower Realized Risk IPOD
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 58.0 / 100 (HOLD) Higher Composite IPOD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IPOD +0.97 pp
ABI: +0.0% · IPOD: +0.97%
3M Horizon IPOD +3.12 pp
ABI: -0.46% · IPOD: +2.66%
6M Horizon IPOD +3.06 pp
ABI: -0.3% · IPOD: +2.76%
1Y Horizon IPOD +3.06 pp
ABI: -0.3% · IPOD: +2.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABI vs IPOD. Trailing 12-month operating profitability (ABI N/A vs IPOD 0.0%) and valuation multiples (ABI N/M vs IPOD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
IPOD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IPOD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IPOD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IPOD Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $210.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABI vs IPOD Key Questions & Quantitative Answers

As of Nov 16, 2026, IPOD (IPOD) is the stronger overall head-to-head candidate over ABI (ABI) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABI carries a Unified Composite Score of 49.0/100 (HOLD) at $24.48 (N/M Forward P/E, N/A operating margin), whereas IPOD carries 58.0/100 (HOLD) at $10.42 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ABI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.1); meanwhile IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IPOD leads the Growth & Scale pillar: ABI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IPOD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABI generates N/A in USD-normalized revenue versus N/A for IPOD. In operating R&D and SG&A reinvestment, ABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IPOD.

IPOD screens cheaper on headline valuation multiples. ABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IPOD trades at N/M Forward P/E, 39.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABI (N/A ROE) versus IPOD (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ABI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 2% Vol realized risk). By comparison, IPOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.00β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.